Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YYB101 plus Irinotecan in Metastatic or Recurrent Colorectal Cancer
NCT04368507Phase 2Completed
- Sponsor
- CellabMED
- Start
- Aug 2019
- Primary completion
- Dec 2021
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of yyb101 in colorectal cancer (CRC), sponsored by CellabMED. Primary endpoints: Dose Limiting Toxicities at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Started Aug 2019; status: completed.
02
Drugs
yyb101
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04368507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04368507.